{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:41:09Z","timestamp":1793814069874,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ40837"],"award-info":[{"award-number":["2023JJ40837"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020980","name":"Peking University Beijing Innovation Center for Engineering Science and Advanced Technology","doi-asserted-by":"publisher","award":["KC2023-JX-0288-PM37"],"award-info":[{"award-number":["KC2023-JX-0288-PM37"]}],"id":[{"id":"10.13039\/501100020980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","award":["YX202211"],"award-info":[{"award-number":["YX202211"]}],"id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2025SF-YBXM-171"],"award-info":[{"award-number":["2025SF-YBXM-171"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lungcan.2025.108883","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:14:40Z","timestamp":1765988080000},"page":"108883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real\u2011world multicenter retrospective study"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-1051","authenticated-orcid":false,"given":"Guoyin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoxiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunXiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2025.108883_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"issue":"21","key":"10.1016\/j.lungcan.2025.108883_b0010","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108883_b0015","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.22.02509","article-title":"US food and drug administration approval summary: nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non-small-cell lung cancer","volume":"41","author":"Akinboro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108883_b0020","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","article-title":"Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial","volume":"9","author":"Lei","year":"2023","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108883_b0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat. Med."},{"issue":"10459","key":"10.1016\/j.lungcan.2025.108883_b0030","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108883_b0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108883_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108883_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102986","article-title":"LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2","volume":"9","author":"Bradley","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2025.108883_b0050","article-title":"65O CheckMate 73L: phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC","volume":"24","author":"Peters","year":"2024","journal-title":"Immuno-Oncol. Technol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108883_b0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2023.09.1452","article-title":"Bintrafusp Alfa with CCRT followed by bintrafusp alfa versus placebo with CCRT followed by durvalumab in patients with unresectable stage III NSCLC: a phase 2 randomized study","volume":"19","author":"Vokes","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108883_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102184","article-title":"Adaptive radiation strategy with V20 limitation associates with survival benefit and lower incidence of symptomatic radiation pneumonitis in stage III NSCLC patients receiving concurrent immunotherapy and thoracic radiation","volume":"51","author":"Song","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.lungcan.2025.108883_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102394","article-title":"Enhancement of prognostic outcomes in stage III non-small cell lung cancer: a retrospective study on neoadjuvant immuno-chemotherapy followed by definitive chemo-radiotherapy","volume":"56","author":"Ding","year":"2025","journal-title":"Transl. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108883_b0070","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab before and after chemoradiation for unresectable stage III non-small cell lung cancer: a phase II nonrandomized controlled trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108883_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1591134","article-title":"Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study","volume":"16","author":"Guan","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108883_b0080","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijrobp.2022.12.042","article-title":"Induction immune checkpoint inhibitors and chemotherapy before definitive chemoradiation therapy for patients with bulky unresectable stage III non-small cell lung cancer","volume":"116","author":"Wang","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2025.108883_b0085","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2023.41.16_suppl.8521","article-title":"Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial","volume":"41","author":"Spicer","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108883_b0090","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108883_b0095","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108883_b0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108883_b0105","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108883_b0110","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108883_b0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108883_b0120","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108883_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1432954","article-title":"A retrospective comparison of induction chemoimmunotherapy versus chemotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in stage III non-small cell lung cancer","volume":"14","author":"Zhao","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108883_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1289207","article-title":"Induction chemoimmunotherapy may improve outcomes of chemoradiotherapy in patients with unresectable stage III NSCLC","volume":"14","author":"Guan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2025.108883_b0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2022.04.033","article-title":"De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer","volume":"171","author":"Bryant","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108883_b0140","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/S1556-0864(23)00378-7","article-title":"123P second progression-free survival (PFS2) after first progression in patients receiving PACIFIC regimen: an exploratory analysis of the Blue Sky observational study","volume":"18","author":"Filippi","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108883_b0145","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.21037\/tlcr-24-362","volume":"13","author":"Dong","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108883_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110040","article-title":"Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: a multi-institutional analysis","volume":"190","author":"Bi","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108883_b0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13014-025-02639-2","article-title":"Optimal dose-volume histogram thresholds for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy","volume":"20","author":"Ma","year":"2025","journal-title":"Radiat. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108883_b0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T17:23:19Z","timestamp":1769448199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"alternative-id":["S0169500225007755"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108883","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real\u2011world multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108883"}}